Recombinant anti-VEGFR2 humanized monoclonal antibody

重组抗VEGFR2全人单克隆抗体

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant anti-VEGFR2 humanized monoclonal antibody
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A